Central serous chorioretinopathy (CSCR) is a vision-threatening eye disease with no validated treatment and unknown pathogens.The disease is seen in young and middle aged groups accompanied by recurrent or chronic progressive loss of visual acuity. Overreaction of mineralocorticoid receptor (MR) pathways has been implicated in pathophysiology of CSCR. No effective drug therapy has been seen for treatment of CSCR. The purpose of this study was to evaluate MR antagonists in treatment of Central serous chorioretinopathy, thus reducing the duration of illness and increasing the quality of life are considered critical. This study is adouble-blind randomized clinical trial (RCT) in patients admitted to Shahid Sadoughi hospital in 2014-2015. Totally 40 patients with a history of acute CSCR were randomized into two groups: Group A treated with placebo and group B treated with spironolactone25 mg/d. Patient demographic, visual acuity(BCVA, LogMAR) and CMT were measured at baseline, two and four weeks later (the Snellen chart and OCT). In improvement of central macular thickness (CMT) and best corrected visual acuity (BCVA), success of treatment was 72.2% (p value0.028). LogMAR change of 0.463 to 0.108 after one month (p value˂0.001) showed positive effect of BCVA in the group treated with Spironolactone.In the treatment group, CMT changed from 550 μm to 311μm, with a 43.43% significant reduction. No drug related complication was observed. Early treatment in the acute phase of CSCR with spironolactone25 mg/d may have clinical efficacy in the improvement of BCVA and CMT changes.
